ERBB2 and neoplasm: Notably, the somatic NGS panel can offer other information with clinical relevance, such as the presence of mutations in BRCA1, BRCA2, PALB2, ERBB2, and ESR1, in addition to molecular changes that can be treated with tumor-agnostic therapies.